Citations : CloneSelect SCP

During biomanufacturing cell lines development, the generation and screening for single‐cell derived subclones using methods that enable assurance of clonal derivation can be resource‐ and time‐intensive. High‐throughput miniaturization, automation, and analytic strategies are often employed to reduce such bottlenecks. The Beacon platform from Berkeley Lights offers a strategy to eliminate these limitations through culturing, manipulating, and characterizing cells on custom nanofluidic chips via software‐controlled operations. However, explicit demonstration of this technology to provide high assurance of a single cell progenitor has not been reported. Here, a methodology that utilizes the Beacon instrument to ensure high levels of clonality is described. It is demonstrated that the Beacon platform can efficiently generate production cell lines with a superior clonality data package, detailed tracking, and minimal resources. A stringent in‐process quality control strategy is established to enable rapid verification of clonal origin, and the workflow is validated using representative Chinese hamster ovary‐derived cell lines stably expressing either green or red fluorescence protein. Under these conditions, a >99% assurance of clonal origin is achieved, which is comparable to existing imaging‐coupled fluorescence‐activated cell sorting seeding methods.

Regulatory agencies say that recombinant proteins intended for therapeutic must be produced from a cell line derived from a single progenitor cell. In addition, single-cell cloning has gained increasing importance as genome editing techniques has entered routine laboratory practice.

The increasing adoption of large protein biologics such as monoclonal antibodies(mAbs) for the treatment of disease has heralded unprecedented growth in the R&D of novel therapeutics and biosimilar, bringing unique challenges to the biopharmaceuticals company.